Compare Incyte Corporation (INCY) vs J M Smucker Co (SJM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs J M Smucker Co — how do they compare? Incyte Corporation trades at $112.77 (market cap $22.85B), while J M Smucker Co trades at $119.43 (market cap $12.76B). The key difference: Incyte Corporation is the larger of the two by market cap, and J M Smucker Co pays a 3.75% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and J M Smucker Co for 74 Days on average.
| INCY | SJM | |
|---|---|---|
Market Cap | $22.85B | $12.76B |
Volume | 1,927,029 | 1,300,545 |
Sector | Health | Consumer Staples |
52-Week High | $129.93 | $132.34 |
52-Week Low | $83.80 | $89.53 |
Typical Hold Time | 33 Days | 74 Days |
Enterprise Value | $18.35B | $19.61B |
Dividend Yield | — | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
SJM stock trades at $119.27, up 2.88% today, with a bullish technical signal from moving averages. The company shows strong earnings momentum with three consecutive quarterly beats, though 2025 results were impacted by a net loss of $1.23B. Analyst consensus is positive with a $138.23 price target, representing 16% upside potential. Recent news highlights strong execution and raised 2027 guidance, while technical indicators show support at $118 and resistance at $120.
The outlook remains cautiously optimistic with earnings momentum and raised guidance supporting upside, but investors face risks from volatile profitability, high debt levels, and competitive pressures in consumer staples. The stock offers value with reasonable P/S and EV/EBITDA multiples, though the elevated P/E ratio requires sustained earnings improvement to justify current valuation levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
